Human lung cancer drug-resistant cell strain and application thereof

By constructing the human lung cancer drug-resistant cell line NCI-H2170/Enhertu-R, the problem of resistance to trastuzumab for HER2-positive lung cancer is solved, and it provides a tool to study drug resistance mechanisms and develop new anti-tumor drugs. It is of great importance. Application prospects.

CN119020289APending Publication Date: 2024-11-26BIORAY PHARMACETICAL(HANGZHOU)CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411293147.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the prior art, HER2-positive lung cancer patients have developed primary and secondary drug resistance to trastuzumab or detrastuzumab treatment, and lacks relevant human lung cancer drug-resistant cell line models, making it difficult to go deeper. Study the mechanism of action of antibody drugs and develop new anti-tumor drugs.

Method used

A human lung cancer drug-resistant cell line NCI-H2170/Enhertu-R was constructed. By continuously induced and gradually increasing the concentration of detratratuzumab, it induced a tolerance that can still grow at a concentration of 13.1 nM. drug cell lines and apply them to screen anti-tumor drugs and study drug resistance mechanisms.

Benefits of technology

It provides an important tool for studying tumor resistance mechanisms and developing new anti-tumor drugs. It has high scientific research and production application value, can help analyze morphological and biological changes after cell resistance, and guide patients to use drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005045192790000051
    Figure BDA0005045192790000051
  • Figure HDA0005045192800000011
    Figure HDA0005045192800000011
  • Figure HDA0005045192800000012
    Figure HDA0005045192800000012
Patent Text Reader

Abstract

The invention belongs to the field of biology, and particularly relates to a human lung cancer drug-resistant cell strain and application thereof. The invention constructs a human lung cancer cell drug-resistant cell strain for the first time, and the human lung cancer cell drug-resistant cell strain can be used for analyzing morphological and biological phenotype changes of human lung cancer cells after drug resistance, researching molecular mechanisms of tumor on drug resistance of detrastuzumab or trastuzumab and a method for reversing tumor drug resistance, and screening other antitumor drugs. Tumor drug resistance markers are found, and novel anti-tumor drugs are screened and evaluated. The method has high scientific research and production application values.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure belongs to the field of biomedical technology, and specifically relates to a human lung cancer resistant cell line and its application. Background Art

[0002] HER2, also known as ErbB2, is a member of the epidermal growth factor receptor (EGFR) family. It is a transmembrane glycoprotein with receptor tyrosine kinase activity encoded by the HER2 gene. As an important tumor marker molecule, HER2 has gene amplification or protein overexpression in a variety of malignant tumors such as breast cancer, gastric cancer, ovarian cancer, lung cancer, and prostate cancer, which are clinically called HER2-positive tumors. According to statistics, the proportion of HER2 overexpression in breast cancer patients is as high as 20-30%. HER2-positive tumors are clinically manifested as high malignancy, insensitivity to radiotherapy and chemotherapy, and easy recurrence and metastasis after treatment. Its potential harm is greater (see Ross JS, Fletcher JA, (1999) The HER2 / neu oncogene: prognostic factor, predictive factor and target for therapy, Semin Cancer Biol, 9: 125-138). In addition, studies have found that HER2 is overexpressed in lung cancer, which is related to the type of lung cancer, degree of cell differentiation, resistance to radiotherapy and chemotherapy, and poor prognosis (see Li Wenyan et al., Research Progress of HER2 Gene in Lung Cancer, Medical Research and Education, 2010, Vol. 27, No. 4).

[0003] Since HER2 has significant differences in expression levels between normal cells and tumor cells, it has become an ideal target for tumor immunobiological therapy. For the research on anti-tumor drugs targeting HER2, in 1998, the US FDA approved the first humanized monoclonal antibody drug trastuzumab (trade name Herceptin) for marketing. Today, the use of trastuzumab combined with chemotherapy drugs has become an internationally recognized standard treatment for HER2-positive advanced metastatic breast cancer. Compared with traditional chemotherapy methods, the use of this combined chemotherapy regimen can significantly improve the treatment effect of breast tumors. In 2010, the US FDA approved trastuzumab for the treatment of HER2-positive advanced gastric cancer.

[0004] Enhertu, Chinese name: Youhede, generic name: Detrastuzumab, is an antibody-drug conjugate (ADC) targeting HER2. Enhertu is a drug used to treat adults with unresectable or metastatic HER2-positive breast cancer and adult patients with metastatic non-small cell lung cancer with activating mutations. It is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co., Ltd.

[0005] At present, a large number of clinical applications have found that many HER2-positive tumor patients have developed primary and secondary resistance to trastuzumab or de-trastuzumab. Therefore, researchers need to conduct in-depth research on the mechanism of action of antibody drugs in order to better carry out personalized treatment of tumors. Tumor or cancer resistant cell lines are important research tools for analyzing the resistance mechanism of tumor or cancer cells and developing new drugs that can combat tumor or anticancer resistance. Although a variety of tumor or anticancer resistant cell lines have been established at home and abroad, there are few reports on Enhertu's human lung cancer resistant cell lines. Summary of the invention

[0006] The purpose of the present disclosure is to provide a human lung cancer resistant cell line and its application.

[0007] In the first aspect, a drug-resistant cell strain is provided. The drug-resistant cell strain is named as human lung cancer resistant cell strain NCI-H2170 / Enhertu-R, and its deposit number is CCTCC NO: C2024231.

[0008] In some embodiments, the resistant cell line is resistant to trastuzumab.

[0009] In some embodiments, the resistant cell line is resistant to trastuzumab.

[0010] In some embodiments, the drug-resistant cell line has a drug-resistant concentration of at least 1.31 nM to trastuzumab, such as 1.31 nM to 3 nM, 3 nM to 5 nM, 5 nM to 7 nM, 7 nM to 9 nM, 9 nM to 13.1 nM; non-limiting examples include about 1.31 nM, about 3 nM, about 5 nM, about 7 nM, about 9 nM, about 13.1 nM, or any value between any two values. In some embodiments, the drug-resistant cell line has a drug-resistant concentration of 13.1 nM to trastuzumab.

[0011] In a second aspect, the use of the drug-resistant cell strain in screening anti-tumor or anti-cancer drugs is provided. In some embodiments, the use of the drug-resistant cell strain in screening drugs for tumors or cancers resistant to HER2 antagonists is provided. In some embodiments, the use of the drug-resistant cell strain in screening drugs for tumors or cancers resistant to anti-HER2 antibodies is provided. In some embodiments, the use of the drug-resistant cell strain in screening drugs for tumors or cancers resistant to anti-HER2 antibody-drug conjugates is provided.

[0012] In a third aspect, provided is the use of the drug-resistant cell line in the preparation of anti-tumor or anti-cancer drugs.

[0013] In a fourth aspect, the use of the drug-resistant cell line in studying the drug resistance mechanism of tumors or cancers is provided. In some embodiments, the use of the drug-resistant cell line in studying the drug resistance mechanism of tumors in vitro is provided.

[0014] In some embodiments, the tumor or cancer is selected from the group consisting of breast cancer, lung cancer, urethral cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, bladder cancer, gastric cancer, gastrointestinal stromal tumors, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, colon cancer, rectal cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasma cell neoplasm, myeloma, esophageal gastric junction cancer, and sarcoma.

[0015] In some embodiments, the cancer is breast cancer, gastric cancer, lung cancer, and esophagogastric junction cancer. In some embodiments, the tumor is an advanced solid tumor.

[0016] In some embodiments, the gastric cancer is metastatic gastric cancer, and the breast cancer is metastatic breast cancer, HER2+ breast cancer, or triple-negative breast cancer. In some embodiments, the lung cancer is metastatic non-small cell lung cancer.

[0017] In a fifth aspect, the use of the drug-resistant cell line in establishing a drug-resistant animal model is provided; in some embodiments, the animal model is a breast cancer model, a gastric cancer model, a lung cancer model, or an esophageal gastric junction cancer model. The animal model can be established by subcutaneous tumor implantation or tail vein injection modeling.

[0018] In a sixth aspect, provided is the use of the drug-resistant cell line in analyzing the sensitivity of anticancer drugs in vitro.

[0019] In the seventh aspect, a method for constructing the drug-resistant cell beads is provided.

[0020] In some embodiments, the present disclosure uses human lung cancer cells NCI-H2170 as the induction object, detects IC30 as the initial dosing concentration, and then increases it to IC50 as the dosing concentration, and then continuously increases the drug concentration, and continuously cultures for more than 6 months until NCI-H2170 cells that can still grow normally at Enhertu of 13.1nM, i.e., NCI-H2170 / Enhertu-R cells, are screened, and NCI-H2170 / Enhertu-R cells can still maintain drug resistance after continuous passaging and cryopreservation and recovery.

[0021] The present disclosure adopts a method of continuous induction at low concentration and gradually increasing the concentration of trastuzumab, which effectively induces the formation of human lung cancer resistant cell beads. The construction method disclosed in the present disclosure is simple to operate and can effectively make up for the shortcomings of existing methods.

[0022] The present disclosure constructs for the first time a drug-resistant cell line of human lung cancer cells, which can be used to analyze the changes in morphology and biological phenotypes of human lung cancer cells after they become drug-resistant; study the molecular mechanisms of tumor resistance to dexamethasone or trastuzumab and methods for reversing tumor resistance and screening other anti-tumor drugs; discover tumor resistance markers and screen and evaluate new anti-tumor drugs, etc., and has high scientific research and production application value.

[0023] The present disclosure has important application prospects in studying the drug resistance mechanism of tumors or cancers, reversing the drug resistance of tumors or cancer cells, guiding patients in drug use, and establishing drug-resistant animal models.

[0024] The drug-resistant human lung cancer cell line obtained in the present disclosure is named NCI-H2170 / Enhertu-R, the preservation unit is China Center for Type Culture Collection, the preservation number is CCTCC NO: C2024231, and the preservation date is August 13, 2024. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is the in vitro proliferation inhibition curve of Enhertu on NCI-H2170 cells.

[0026] Figure 2 Schematic diagram of the cell morphology of NCI-H2170 and NCI-H2170 / Enhertu-R cells under optical microscope.

[0027] Figure 3 Schematic diagram of Enhertu's inhibition of proliferation of NCI-H2170 and NCI-H2170 / Enhertu-R in vitro.

[0028] Figure 4 Schematic diagram of the in vitro proliferation inhibition of NCI-H2170 and NCI-H2170 / Enhertu-R by Dxd.

[0029] Figure 5 Schematic diagram of the in vitro proliferation inhibition of NCI-H2170 and NCI-H2170 / Enhertu-R by Trastuzumab.

[0030] Figure 6 Schematic diagram of HER2 expression in NCI-H2170 and NCI-H2170 / Enhertu-R cells (Figure A is the result of flow cytometry detection, Figure B is the result of WB detection, and MFI in the figure refers to mean fluorescence intensity). DETAILED DESCRIPTION

[0031] definition

[0032] The term "comprising" encompasses the meanings of "including" as well as "consisting of."

[0033] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to practice in the art, "about" can mean 3 or more standard deviations. Alternatively, "about" can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within a certain order of magnitude of a certain value, preferably within 5 times, more preferably within 2 times.

[0034] Cellular drug resistance refers to the ability of cells to resist drugs to a certain extent, so that cells that were originally sensitive to drugs no longer have the expected effect on them after exposure to the drugs.

[0035] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur. As used in the specification and claims, the singular forms "a", "an" include the corresponding plural referents unless the content clearly dictates otherwise.

[0036] The terms "HER2 receptor antagonist" and "HER2 antagonist" refer to compounds that inhibit the expression or function of HER2 protein or gene. For the purposes of this disclosure, HER2 antagonists refer to, for example, receptor tyrosine kinase inhibitors, especially HER2 receptor protein inhibitors, examples of which include antibodies that bind to HER2, anti-HER2 antibody-drug conjugates, and small molecule inhibitors that inhibit HER2 activity. "HER2 antagonists" in the present invention particularly refer to anti-HER2 antibodies and anti-HER2 antibody-drug conjugates.

[0037] The term "trastuzumab" is a mouse anti-HER2 antibody 4D5, which is called a recombinant humanized anti-HER2 monoclonal antibody (huMAb4D5-8, rhuMAb HER2), and is sold under the trade names of Herceptin, Ogivri and Herzuma. Trastuzumab has the CDR regions defined in U.S. Patent 5,821,337. As used herein, "trastuzumab" also includes biosimilars, such as Kanjinti (trastuzumab-anns).

[0038] The term "Trastuzumab Deruxtecan, also known as DS-8201a, refers to an antibody-drug conjugate consisting of trastuzumab, a linker, and a topoisomerase I inhibitor deruxtecan derivative. Trastuzumab Deruxtecan is marketed in the United States under the trade name Sales. It can be prepared with reference to WO2015115091A1 and has the following structure:

[0039] Where n is 8.

[0040] The present disclosure will be described below in conjunction with specific embodiments, but the content of the present disclosure is not limited thereto.

[0041] Unless otherwise specified, the reagents and instruments used in the following methods are commonly used reagents and instruments in the art and can be obtained commercially; the methods used are conventional methods in the art, and those skilled in the art can undoubtedly perform the methods and obtain corresponding results based on the contents described in the embodiments.

[0042] Those skilled in the art will appreciate that the embodiments describe the present disclosure by way of example and are not intended to limit the scope of protection claimed by the present disclosure.

[0043] The room temperature described in the examples is the conventional room temperature in the art, generally 18-26°C.

[0044] Example 1. Construction of NCI-H2170 / Enhertu-R

[0045] This example discloses a method for constructing NCI-H2170 / Enhertu-R, which is as follows:

[0046] Human lung cancer cells NCI-H2170 (purchased from Nanjing Kebai Biological Co., Ltd.) were cultured in RPMI 1640 medium containing 10% fetal bovine serum in a 37° C., 5% CO 2 incubator. In order to obtain the in vitro proliferation inhibition curve of Enhertu on NCI-H2170 cells, 4000 cells / well were seeded in a 96-well plate in the logarithmic phase, and Enhertu was given on the next day (Enhertu was prepared by reference to WO2015115091A1). The initial concentration of Enhertu was 333.3 nM, and 9 points were obtained by 5-fold gradient continuous dilution. A blank control group was set up, and 3 replicates were set up in each group. After 6 days of Enhertu treatment, 100 μL CellTiter-Glo reagent (purchased from Promega, catalog number G7572) was added to each well, and the culture plate was placed on an orbital shaker for mixing for 3 minutes, and then the culture plate was placed at room temperature for incubation for 15 minutes. The luminescent signal was detected by a microplate reader to obtain the in vitro proliferation inhibition curve of Enhertu on NCI-H2170 cells, as shown in the figure. Figure 1 Finally, the IC30 value of Enhertu's inhibition of NCI-H2170 cell proliferation in vitro was calculated by Graphpad to be 0.33 nM. In this experiment, the cells were induced to resist the drug by increasing the drug concentration, so the initial concentration of Enhertu for inducing resistance in cells was 0.33 nM, which was its IC30.

[0047] NCI-H2170 cells were trypsinized and counted at 7×10 5 The cells were inoculated at a density of 10 cm in a cell culture dish. The next day, NCI-H2170 was treated with 0.33 nM Enhertu, and the cells were passaged 6 days after drug intervention. It was found that NCI-H2170 cells could grow stably at a concentration of 0.33 nM Enhertu after continuous administration for about one month, and then the drug concentration of Enhertu was increased to IC50, i.e. 1 nM. After the cells were stabilized by continuous subculture at the IC50 concentration, the concentration of Enhertu continued to be increased, and the cells were cultured continuously for more than 6 months until the NCI-H2170 cells that could still grow normally at a concentration of 13.1 nM Enhertu were screened, i.e. NCI-H2170 / Enhertu-R cells. The obtained NCI-H2170 / Enhertu-R cells were deposited in the China Center for Type Culture Collection, with the deposit number CCTCC NO: C2024231 and the deposit date: August 13, 2024.

[0048] Example 2. Cell morphology of NCI-H2170 and NCI-H2170 / Enhertu-R cells under optical microscope

[0049] The cell morphology of NCI-H2170 and NCI-H2170 / Enhertu-R cells in the logarithmic growth phase was observed under an optical microscope. The cells grew in clusters before and after drug resistance. There was no significant difference in the morphology of NCI-H2170 and NCI-H2170 / Enhertu-R cells. According to the cell size analysis results of the cell counter, it was found that the size of NCI-H2170 / Enhertu-R cells was slightly larger than that of NCI-H2170 cells. Figure 2 shown.

[0050] Example 3. In vitro proliferation inhibition experiment of Enhertu on NCI-H2170 and NCI-H2170 / Enhertu-R cells

[0051] This example studies the effect of Enhertu on the proliferation of NCI-H2170 and NCI-H2170 / Enhertu-R cells in vitro, as follows:

[0052] NCI-H2170 and NCI-H2170 / Enhertu-R cells were digested with trypsin, counted, and seeded in 96-well plates at 4000 cells per well. The next day, they were treated with Enhertu and DXd (deruxtecan, purchased from Selleck, catalog number E2891), respectively. The initial concentration of Enhertu was 333.3 nM, and 9 points were obtained by 5-fold gradient dilution. The initial concentration of DXd was 100 nM, and 9 points were obtained by 3-fold gradient dilution. A blank control group was set up, and 3 replicates were set up for each group. After 5 days of Enhertu and DXd treatment, 100 μL of CellTiter-Glo reagent (purchased from Promega, catalog number G7572) was used to mix the culture plate on an orbital shaker for 3 minutes, and then the culture plate was incubated at room temperature for 10 minutes. The luminescent signal was detected by a microplate reader, and the in vitro proliferation inhibition curves of Enhertu and DXd on NCI-H2170 and NCI-H2170 / Enhertu-R cells were drawn and the IC50 values ​​were calculated. The results are shown in Figure 3 , Figure 4 And as shown in Table 1.

[0053] Table 1 IC50 values ​​of Enhertu for inhibition of proliferation of NCI-H2170 and NCI-H2170 / Enhertu-R cells in vitro

[0054]

[0055] The results showed that Enhertu had a significant in vitro proliferation inhibitory effect on NCI-H2170 cells, with an IC50 value of 0.58nM, while the in vitro proliferation inhibitory IC50 of Enhertu on NCI-H2170 / Enhertu-R cells was 230.4nM, indicating that NCI-H2170 / Enhertu-R had good resistance to Enhertu; while there was no significant difference in the proliferation inhibitory effect of DXd on NCI-H2170 and NCI-H2170 / Enhertu-R, with IC50 values ​​of 1.247nM and 2.117nM, respectively, further indicating that the resistance of NCI-H2170 / Enhertu-R to Enhertu is not due to resistance to its small molecules.

[0056] Example 4. In vitro proliferation inhibition experiment of NCI-H2170 and NCI-H2170 / Enhertu-R cells by trastuzumab

[0057] This example studies the effect of Trastuzumab on the proliferation of NCI-H2170 and NCI-H2170 / Enhertu-R cells in vitro, as follows:

[0058] NCI-H2170 and NCI-H2170 / Enhertu-R cells were digested with trypsin, counted, and seeded in 96-well plates at a density of 4000 cells per well. The next day, they were treated with Trastuzumab (purchased from Selleck, catalog number A2007). The initial concentration of Trastuzumab was 343.6 nM, and it was continuously diluted in a 5-fold gradient to obtain 9 points. At the same time, a blank control group was set up, and 3 replicates were set up in each group. After 6 days of Trastuzumab treatment, 100 μL CellTiter-Glo reagent (purchased from Promega, catalog number G7572) was added to each well, the culture plate was placed on an orbital shaker for mixing for 3 minutes, and then the culture plate was placed at room temperature for incubation for 15 minutes. The luminescent signal was detected with an enzyme reader, and the in vitro proliferation inhibition curve of Trastuzumab on NCI-H2170 and NCI-H2170 / Enhertu-R cells was drawn and the IC50 value was calculated.

[0059] The results are as follows Figure 5 As shown, Trastuzumab showed obvious differences in its killing effect on the two. It had a significant inhibitory effect on the in vitro proliferation of NCI-H2170 cells, but had no inhibitory effect on the in vitro proliferation of NCI-H2170 / Enhertu-R cells, indicating that NCI-H2170 / Enhertu-R cells also have good resistance to Trastuzumab.

[0060] Example 5. Detection of HER2 expression levels in NCI-H2170 and NCI-H2170 / Enhertu-R cells

[0061] Flow cytometry and immunoblotting were used to detect the expression of HER2 on the surface of NCI-H2170 and NCI-H2170 / Enhertu-R cells, respectively.

[0062] The expression of HER2 on the cell surface was detected by flow cytometry. NCI-H2170 cells and NCI-H2170 / Enhertu-R cells in culture were digested with trypsin, centrifuged, and counted. 5×10 5 Each cell was placed in a 1.5 mL centrifuge tube, centrifuged, washed with Cell staining buffer (purchased from Biolegend, catalog number 420201), added with 100 μL Cell staining buffer, and then added with 5 μL HER2 flow cytometry antibody (purchased from Biolegend, catalog number 357806), and at the same time, its isotype control APC IgG1 antibody (purchased from Biolegend, catalog number 400122) was added with the same amount of antibody, incubated on ice for 30 minutes, washed twice with buffer, and then added with 500 μL buffer to each tube, and the expression of HER2 on the cell surface was detected by flow cytometry.

[0063] Western blotting was used to detect the expression of HER2 protein in NCI-H2170 and NCI-H2170 / Enhertu-R cells. NCI-H2170 cells and NCI-H2170 / Enhertu-R cells in culture were digested with trypsin, centrifuged, counted, and 1×10 6After washing with PBS, RIPA (containing phosphatase and protease inhibitors) was added for protein extraction, and then quantified with a BCA protein concentration assay kit (purchased from Solarbio, catalog number 2310007). 10 μg of protein was loaded and separated by 4-20% gradient precast gel (purchased from Bio-red, catalog number 4561096) at a constant voltage of 150 V. The membrane was transferred at a constant current of 260 mA for 2 hours, and blocked at room temperature for 1 hour with 5% skim milk powder. The cells were washed three times with TBS-T solution containing 0.05% Tween-20, and HER2 antibody (purchased from CST) was added at a dilution ratio of 1:1000. , Catalog No. 2242S), p-HER2 antibody (Tyr1248) (purchased from CST, Catalog No. 2247S), β-actin antibody (purchased from CST, Catalog No. 8457S), incubated at 4°C overnight, washed 3 times with TBS-T solution containing 0.05% Tween-20, added anti-rabbit IgG-HRP-linked secondary antibody (purchased from CST, Catalog No. 7074S) and incubated at room temperature for 1 hour, washed 3 times with TBS-T solution containing 0.05% Tween-20, added ECL luminescent solution (purchased from Bio-red, Catalog No. 1705061) for luminescence, and developed with an imager. The results are shown in Figure 6 shown.

[0064] The results showed that the expression of HER2 in NCI-H2170 / Enhertu-R cells was significantly reduced compared with that in NCI-H2170 cells, suggesting that this may be the reason for the cell resistance.

Claims

1. A drug-resistant cell line, characterized in that: The drug-resistant cell line is named as human lung cancer resistant cell line NCI-H2170 / Enhertu-R, and its preservation number is CCTCC NO: C2024231.

2. The drug-resistant cell line according to claim 1, characterized in that The drug-resistant cell line is resistant to trastuzumab and de-trastuzumab.

3. The drug-resistant cell line according to claim 2, characterized in that The drug-resistant cell line has a drug-resistant concentration of at least 1.31 nM to trastuzumab.

4. The drug-resistant cell line according to claim 3, characterized in that The drug-resistant concentration of the drug-resistant cell line is 13.1 nM.

5. Use of the drug-resistant cell line according to any one of claims 1 to 4 in screening anti-tumor or anti-cancer drugs.

6. Use of the drug-resistant cell line according to any one of claims 1 to 4 in the preparation of anti-tumor or anti-cancer drugs.

7. Use of the drug-resistant cell line according to any one of claims 1 to 4 in studying the drug resistance mechanism of tumors or cancers.

8. The use according to any one of claims 5 to 7, wherein the tumor or cancer is selected from the group consisting of breast cancer, lung cancer, urethral cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, bladder cancer, gastric cancer, gastrointestinal stromal tumors, cervical cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, colon cancer, rectal cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasma cell tumor, myeloma, esophageal gastric junction cancer and sarcoma.

9. The use according to claim 8, characterized in that: The cancer is breast cancer, stomach cancer, lung cancer or esophageal gastric junction cancer.

10. Use of the drug-resistant cell line according to any one of claims 1 to 4 in establishing a drug-resistant animal model; preferably, the animal model is a breast cancer model, a gastric cancer model, a lung cancer model or an esophageal gastric junction cancer model.